This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (33) Citing Articles via Google Scholar Google Scholar Articles by Hodgkinson, K. A. Articles by Connors, S. P. Search for Related Content PubMed PubMed Citation Articles by Hodgkinson, K. A. Articles by Connors, S. P.

The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5)

Kathy A. Hodgkinson, MSc^*,, Patrick S. Parfrey, MD, FRCPC, FACP^*,*, Anne S. Bassett, MD, FRCPC^,, Christine Kupprion, MD, Jörg Drenckhahn, MD, Mark W. Norman, MD, MRCP, Ludwig Thierfelder, MD, Susan N. Stuckless, MSc^*, Elizabeth L. Dicks, MSc^*, William J. McKenna, MD, FRCP^|| and Sean P. Connors, MD, DPhil, FRCPC^¶

^* Clinical Epidemiology Unit
Discipline of Genetics, Memorial University, Health Sciences Centre, St. John's, Newfoundland, Canada
Clinical Genetics Research Program, Centre for Addiction & Mental Health, University of Toronto, Toronto, Ontario, Canada
Max-Delbrück Centrum fur Molekulare Medizin, Berlin, Germany
^|| The Heart Hospital, London, England
^¶ Division of Cardiology, Memorial University, St. John's, Newfoundland, Canada

View larger version (16K): [in a new window]   Figure 1 Part of one of 11 autosomal-dominant families with arrhythmogenic right ventricular cardiomyopathy linked to 3p25 showing family members at high risk (n = 197), low risk (n = 92), and unknown (n = 78) status.

View larger version (16K): [in a new window]   Figure 2 Time to death or last follow-up (censored) in high-risk males and females with arrhythmogenic right ventricular cardiomyopathy linked to 3p25.

View larger version (16K): [in a new window]   Figure 3 (A) Time to death or last follow-up (censored) in 30 male subjects at high-risk for arrhythmogenic right ventricular cardiomyopathy linked to 3p25 who received implantable cardioverter-defibrillators (ICDs) and 36 matched control subjects. (B) Time to death or last follow-up (censored) in 18 female subjects at high risk for arrhythmogenic right ventricular cardiomyopathy linked to 3p25 who received ICDs and 22 matched control subjects.

View larger version (20K): [in a new window]   Figure 4 Time to first appropriate discharge or last follow-up (censored) for sustained ventricular tachycardia (VT) and for VT >240 beats/min in males who received an implantable cardioverter-defibrillator and time to death or last follow-up (censored) in matched controls with arrhythmogenic right ventricular cardiomyopathy linked to 3p25.